"Chemokine CCL5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CC-type chemokine that is a chemoattractant for EOSINOPHILS; MONOCYTES; and LYMPHOCYTES. It is a potent and selective eosinophil chemotaxin that is stored in and released from PLATELETS and activated T-LYMPHOCYTES. Chemokine CCL5 is specific for CCR1 RECEPTORS; CCR3 RECEPTORS; and CCR5 RECEPTORS. The acronym RANTES refers to Regulated on Activation, Normal T Expressed and Secreted.
Descriptor ID |
D018946
|
MeSH Number(s) |
D12.644.276.374.200.110.250 D12.776.467.374.200.110.250 D23.125.300.110.250 D23.469.200.110.250 D23.529.374.200.110.250
|
Concept/Terms |
Chemokine CCL5- Chemokine CCL5
- CCL5, Chemokine
- RANTES Protein, T-Cell
- RANTES Protein, T Cell
- T-Cell RANTES Protein
- CCL5 Chemokine
- Chemokine, CCL5
- RANTES
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CCL5".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CCL5".
This graph shows the total number of publications written about "Chemokine CCL5" by people in this website by year, and whether "Chemokine CCL5" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 1 | 2 |
2004 | 1 | 0 | 1 |
2005 | 1 | 1 | 2 |
2006 | 1 | 1 | 2 |
2007 | 0 | 1 | 1 |
2008 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2013 | 2 | 0 | 2 |
2016 | 0 | 1 | 1 |
2018 | 2 | 1 | 3 |
2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemokine CCL5" by people in Profiles.
-
Wang Y, Tiruthani K, Li S, Hu M, Zhong G, Tang Y, Roy S, Zhang L, Tan J, Liao C, Liu R. mRNA Delivery of a Bispecific Single-Domain Antibody to Polarize Tumor-Associated Macrophages and Synergize Immunotherapy against Liver Malignancies. Adv Mater. 2021 Jun; 33(23):e2007603.
-
Fahey LM, Guzek R, Ruffner MA, Sullivan KE, Spergel J, Cianferoni A. EMSY is increased and activates TSLP & CCL5 expression in eosinophilic esophagitis. Pediatr Allergy Immunol. 2018 08; 29(5):565-568.
-
Popik W, Khatua A, Hildreth JEK, Lee B, Alcendor DJ. Phosphorodiamidate morpholino targeting the 5' untranslated region of the ZIKV RNA inhibits virus replication. Virology. 2018 06; 519:77-85.
-
Singh SK, Mishra MK, Eltoum IA, Bae S, Lillard JW, Singh R. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep. 2018 01 22; 8(1):1323.
-
Pulliam SR, Pellom ST, Shanker A, Adunyah SE. Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis. Cytokine. 2016 08; 84:74-87.
-
Gangwani MR, Noel RJ, Shah A, Rivera-Amill V, Kumar A. Human immunodeficiency virus type 1 viral protein R (Vpr) induces CCL5 expression in astrocytes via PI3K and MAPK signaling pathways. J Neuroinflammation. 2013 Nov 13; 10:136.
-
Nookala AR, Shah A, Noel RJ, Kumar A. HIV-1 Tat-mediated induction of CCL5 in astrocytes involves NF-?B, AP-1, C/EBPa and C/EBP? transcription factors and JAK, PI3K/Akt and p38 MAPK signaling pathways. PLoS One. 2013; 8(11):e78855.
-
Singh R, Singh S, Briles DE, Taub DD, Hollingshead SK, Lillard JW. CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes. Vaccine. 2012 Feb 01; 30(6):1181-90.
-
Sakthivel SK, Singh UP, Singh S, Taub DD, Igietseme JU, Lillard JW. CCL5 regulation of mucosal chlamydial immunity and infection. BMC Microbiol. 2008 Aug 13; 8:136.
-
Armah HB, Wilson NO, Sarfo BY, Powell MD, Bond VC, Anderson W, Adjei AA, Gyasi RK, Tettey Y, Wiredu EK, Tongren JE, Udhayakumar V, Stiles JK. Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children. Malar J. 2007 Nov 12; 6:147.